Apollomics, Inc. (APLM)
| Market Cap | 45.68M |
| Revenue (ttm) | 8.84M |
| Net Income (ttm) | -10.94M |
| Shares Out | 2.20M |
| EPS (ttm) | -7.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,412 |
| Open | 20.00 |
| Previous Close | 22.00 |
| Day's Range | 19.93 - 21.73 |
| 52-Week Range | 3.66 - 42.12 |
| Beta | 1.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 27, 2026 |
About APLM
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in... [Read more]
Financial Performance
In 2025, Apollomics's revenue was $8.84 million, an increase of 776.31% compared to the previous year's $1.01 million. Losses were -$10.94 million, -79.69% less than in 2024.
Financial StatementsNews
Apollomics Inc trading halted, volatility trading pause
11:50 EDT Apollomics (APLM) Inc trading halted, volatility trading pause
Apollomics receives noncompliance notice from Nasdaq
Apollomics (APLM) announced that it has received a notice from Nasdaq dated June 18 stating that the company is not in compliance with the requirement to maintain a minimum Market…
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology dru...
Apollomics Registration statement: Registration filing
Apollomics filed a registration statement on May 15, 2026, providing details about a securities offering with the SEC.
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than ...
Apollomics Annual report: Q4 2025
Apollomics has published its Q4 2025 annual report on April 27, 2026.
Apollomics Earnings release: Q4 2025
Apollomics released its Q4 2025 earnings on April 27, 2026, summarizing the period's financial results.
Apollomics Inc. Announces $2.0 Million Bridge Financing
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Pr...
Apollomics files to sell 279,775 Class A Ordinary shares for holders
17:18 EDT Apollomics (APLM) files to sell 279,775 Class A Ordinary shares for holders
Apollomics Registration statement: Registration Filing
Apollomics filed a registration statement on March 9, 2026, providing details about a securities offering with the SEC.
Apollomics Inc trading resumes
16:00 EST Apollomics (APLM) Inc trading resumes
Apollomics Inc trading halted, volatility trading pause
15:51 EST Apollomics (APLM) Inc trading halted, volatility trading pause
Apollomics Reports First Half 2025 Financial Results
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology dru...
Apollomics Earnings release: Q2 2025
Apollomics released its Q2 2025 earnings on December 22, 2025, summarizing the period's financial results.
Apollomics Inc trading resumes
11:45 EST Apollomics (APLM) Inc trading resumes
Apollomics Inc trading halted, volatility trading pause
11:40 EST Apollomics (APLM) Inc trading halted, volatility trading pause
Apollomics announces settlement of Cayman litigation
Apollomics (APLM) announced entering into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited, entities represented by Triwise Capital Manag...
Apollomics Announces Settlement of Cayman Litigation
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” o...
Apollomics Inc trading resumes
11:14 EST Apollomics (APLM) Inc trading resumes
Apollomics Inc trading halted, volatility trading pause
11:09 EST Apollomics (APLM) Inc trading halted, volatility trading pause
Apollomics Announces Changes to its Board of Directors and Composition of Committees
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced...
Apollomics Inc trading resumes
10:05 EDT Apollomics (APLM) Inc trading resumes
Apollomics Inc trading halted, volatility trading pause
10:00 EDT Apollomics (APLM) Inc trading halted, volatility trading pause
Apollomics Inc trading resumes
13:11 EDT Apollomics (APLM) Inc trading resumes